A 41-year-old woman recently diagnosed with limited cutaneous systemic sclerosis seeks care for progressively worsening color changes and throbbing pain in her fingers upon cold exposure. Over several years, her symptoms progressively escalate despite compliance with each prescribed treatment regimen, eventually leading to severe digital ischemia and impending gangrene. Arrange the following therapies for secondary Raynaud phenomenon in the standard stepwise order of clinical escalation, from initial baseline management to interventions for medically refractory, limb-threatening disease.
- 1Implementation of behavioral modifications, including strict cold avoidance and smoking cessation
- 2Initiation of an oral dihydropyridine calcium channel blocker (e.g., nifedipine)
- 3Addition of a phosphodiesterase-5 (PDE-5) inhibitor (e.g., sildenafil)
- 4Administration of an intravenous prostanoid (e.g., epoprostenol)
- 5Performance of a digital sympathectomy
Cevap
The correct chronological sequence of therapy escalation is: behavioral modifications, followed by oral calcium channel blockers, followed by oral PDE-5 inhibitors, then intravenous prostanoids, and finally digital sympathectomy.
The management of secondary Raynaud phenomenon follows a strict stepwise escalation to balance efficacy with medication side effects and procedural risks. Treatment always begins with nonpharmacologic behavioral modifications. If vasospastic attacks continue, oral vasodilators are introduced, starting with dihydropyridine calcium channel blockers. If symptoms remain refractory, secondary oral agents like PDE-5 inhibitors are added. Progression to severe ischemic complications, such as digital ulcers, mandates escalation to intravenous prostanoids. Finally, if tissue loss is imminent and all medical therapies fail, surgical sympathectomy is performed.
Adım Adım Çözüm
Anahtar Kavram
Stepwise escalation of therapy for secondary Raynaud phenomenon in systemic sclerosis.